Could white blood cells boost cord transplants for tough leukemia?
NCT ID NCT07372885
First seen Jan 29, 2026 · Last updated Jun 23, 2026 · Updated 17 times
Summary
This trial tests a new way to do cord blood transplants for young adults (ages 16-55) with very poor risk acute myeloid leukemia (AML). Participants get a standard cord blood transplant plus daily infusions of white blood cells called granulocytes for 1 to 7 days. The goal is to see if this combination is safe and can reduce the chance of the leukemia coming back. The study has two parts: first to find the best dose, then to see if it works better than standard transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kings College Hospital NHS Trust
London, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The Christie NHS Foundation Trust
Manchester, United Kingdom
Contact Email: •••••@•••••
Contact
-
The Royal Marsden Hospital NHS Foundation Trust
London, United Kingdom
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cord blood stem cells and granulocytes (white blood cells)
What this could lead to
If successful, this approach could offer a more effective transplant option for young adults with hard-to-treat AML, potentially reducing relapse and improving survival.
What could go wrong
This is an early phase I/II trial with only 50 participants, so results may not apply broadly. The granulocyte infusions can cause fever, rash, and other side effects, and the treatment may not work for everyone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.